LivaNova (NASDAQ:LIVN) coverage initiated by analysts at The Goldman Sachs Group

Goldman Sachs Group initiated coverage on shares of LivaNova (NASDAQ:LIVN – Get a Free Report) in a report issued on Friday, reports Benzinga. The firm set a “buy” rating and a $65.00 price target on the stock. Goldman Sachs Group’s target price would indicate a potential upside of 22.16% from the company’s previous close.

Several other equities analysts have also recently weighed in on the company. Stifel Nicolaus upped their price objective on LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Needham & Company LLC boosted their price objective on LivaNova from $72.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. Robert W. Baird upgraded LivaNova from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $55.00 to $66.00 in a report on Tuesday, September 17th . Finally, Baird RW upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $69.83.

See the latest stock analysis on LivaNova

LivaNova price performance

Shares of LIVN stock opened at $53.21 on Friday. The stock has a 50 day moving average price of $48.63 and a two hundred day moving average price of $53.37. The stock has a market cap of $2.88 billion, a PE ratio of -88.68 and a beta of 1.00. The company has a current ratio of 3.45, a quick ratio of 2.94, and a debt-to-equity ratio of 0.49. LivaNova has a 1 year low of $42.75 and a 1 year high of $64.47.

LivaNova (NASDAQ:LIVN – Get Your Free Report ) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.15. The company had revenue of $318.60 million during the quarter, compared to analysts’ expectations of $305.05 million. LivaNova had a positive return on equity of 13.77% and a negative net margin of 1.37%. equities analysts anticipate that LivaNova will post 2.58 EPS for the current fiscal year.

Institutional investors intervene on LivaNova

Hedge funds and other institutional investors have recently made changes to their positions in the business. Fifth Third Bancorp grew its position in shares of LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after purchasing an additional 332 shares in the last quarter. Hexagon Capital Partners LLC raised its position in shares of LivaNova by 117.8% in the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after purchasing an additional 370 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in shares of LivaNova in the first quarter valued at approximately $84,000. Canada Pension Plan Investment Board purchased a new stake in shares of LivaNova in the second quarter valued at about $88,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of LivaNova in the first quarter valued at approximately $94,000. 97.64% of shares are currently owned by institutional investors and hedge funds.

About LivaNova

(Get a free report)

LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation and Advanced Circulatory Support segments. The cardiopulmonary segment develops, manufactures and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, infusion tubing systems, cannulas, connect and other related products.

Read more

Get news and reviews for LivaNova Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for LivaNova and related companies with MarketBeat.com’s FREE daily email newsletter.